Greenwich LifeSciences (GLSI) Earnings Date & Reports
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
GLSI is expected to report earnings to -23 cents per share on August 11
Q2'25
Est.
$-0.24
Q1'25
Missed
by $0.03
Q4'24
Est.
$-0.21
Q2'24
Est.
$-0.20
Q1'24
Beat
by $0.01
The last earnings report on May 19 showed earnings per share of -23 cents, missing the estimate of -20 cents. With 6.88K shares outstanding, the current market capitalization sits at 162.83M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GLSI showed earnings on May 19, 2025. You can read more about the earnings report here.